X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins. It is being evaluated for the treatment of patients with locally advanced or metastatic biliary tract cancer.
Lead Product(s): Durvalumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
The financing enables RenovoRx to progress its primary program, the pivotal TIGeR-PaC study, evaluating RenovoGem (gemcitabine) in a clinical trial for locally advanced pancreatic cancer.
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: RenovoGem
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newbridge Securities Corporation
Deal Size: $11.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 15, 2024
Details:
The financing enables RenovoRx to progress its primary program, the pivotal TIGeR-PaC study, evaluating RenovoGem (gemcitabine) in a clinical trial for locally advanced pancreatic cancer.
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: RenovoGem
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newbridge Securities Corporation
Deal Size: $11.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 08, 2024
Details:
Keytruda (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) monoclonal antibody. It is approved for the treatment of resectable non-small cell lung cancer.
Lead Product(s): Pembrolizumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
IMM-1-104 aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, through deep cyclic inhibition of MEK of the MAPK pathway with once-daily oral dosing.
Lead Product(s): IMM-1-104,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: IMM-1-104
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
IMM-1-104 is an oral, once-daily deep cyclic inhibitor, small molecule drug. It is being evaluated for the treatment of patients with RAS-mutant pancreatic ductal adenocarcinoma.
Lead Product(s): IMM-1-104,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: IMM-1-104
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
BMS receives U.S. FDA approval for Opdivo (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
Lead Product(s): Nivolumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
IOA-289 (cambritaxestat) is a novel, first-in-class inhibitor of autotaxin with a unique binding mode. It is being evaluated for the treatment of pancreatic cancer.
Lead Product(s): Cambritaxestat,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: IOA-289
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. It is being developed for the treatment of pancreatic cancer.
Lead Product(s): Nadunolimab,Carboplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
BL-8040 (motixafortide) is a CXCR4 inhibitor, which is being evaluated in combination with cemiplimab, and standard of care chemotherapies for the treatment of Pancreatic ductal adenocarcinoma.
Lead Product(s): Motixafortide,Cemiplimab,Gemcitabine
Therapeutic Area: Oncology Product Name: BL-8040
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
Keytruda (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) monoclonal antibody. It is being evaluated for the treatment of resectable non-small cell lung cancer.
Lead Product(s): Pembrolizumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
IMM-1-104 is an oral, once-daily deep cyclic inhibitor, small molecule drug. It is being evaluated for the treatment of patients with pancreatic ductal adenocarcinoma.
Lead Product(s): IMM-1-104,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: IMM-1-104
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. It is being developed for the treatment of pancreatic cancer.
Lead Product(s): Nadunolimab,Carboplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
G1T28 (trilaciclib) is an IV-administered transient CDK 4/6 inhibitor, which is being evaluated in combination with gemcitabine & carboplatin for the treatment of metastatic triple negative breast cancer.
Lead Product(s): Trilaciclib,Gemcitabine,Carboplatin
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. It is being developed for the treatment of triple negative breast cancer, non-small cell lung cancer & pancreatic cancer.
Lead Product(s): Nadunolimab,Carboplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
VCN-01 is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma. It is being evaluated in phase 2 clinical trials for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): VCN-01,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
Loqtorzi (toripalimab-tpzi) is an anti-PD-1 monoclonal antibody, which is an approved product in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
The net proceeds will be used for the development of SBP-101 (ivospemin), which is designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 01, 2024
Details:
The net proceeds will be used for the development of SBP-101 (ivospemin), which is designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 29, 2024
Details:
The company intends to use the net proceeds for the clinical development of SBP-101 (ivospemin), which is designed to induce polyamine metabolic inhibition (PMI) for metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 29, 2024
Details:
The net proceeds will focus on the development of RenovoGem (gemcitabine), a novel oncology drug-device combination product for the treatment of locally advanced pancreatic cancer.
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: RenovoGem
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Paulson Investment Company
Deal Size: $6.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 29, 2024
Details:
FG-3019 (pamrevlumab) is a CTGF inhibitor monoclonal antibody, which is being evaluated in phase 2/3 clinical trials in combination with gemcitabine & nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Pamrevlumab,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: FG-3019
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
SBP-101 (ivospemin) is a small molecule AMD1/ODC1 inhibitor. It is being evaluated in phase 2/3 clinical trials in combination with gemcitabine & nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
ACT-IOP-003 is an implantable iontophoretic product designed to safely achieve high concentration of gemcitabine in the pancreas. It is being evaluated in preclinical studies for the treatment of locally advanced nonresectable (LANR) pancreatic cancer.
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: ACT-IOP-003
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
Loqtorzi (toripalimab-tpzi) is a PD-1 receptor inhibitor, enabling the immune system to activate and kill the tumor. It is approved for the first-line treatment of adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
Loqtorzi (toripalimab-tpzi) is a PD-1 receptor inhibitor, enabling the immune system to activate and kill the tumor. It is approved for the first-line treatment of adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy.
Lead Product(s): Toripalimab-tpzi,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
LSTA1 (certepetide) is an investigational drug designed to activate a novel uptake pathway that allows co-administered anti-cancer drugs to penetrate solid tumors more effectively. It is being evaluated for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): LSTA1,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: LSTA1
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
Opdivo (nivolumab) is a PD-L1 Inhibitor Antibody drug candidate in combination with cisplatin/gemcitabine which is currently being evaluated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma via intravenous infusion.
Lead Product(s): Nivolumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
TAR-200 (gemcitabine) is a DNA polymerase inhibitor. It is under phase 2 clinical evaluation in combination with Cetrelimab for the treatment of BCG unresponsive non-muscle-invasive bladder cancer.
Lead Product(s): Gemcitabine,Cetrelimab
Therapeutic Area: Oncology Product Name: TAR-200
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
ADI-PEG 20 (pegargiminase) is an Arginine Degrader Enzyme drug candidate, which is currently being evaluating clinical trial studies with patients for the treatment of Leiomyosarcoma.
Lead Product(s): Pegargiminase,Gemcitabine,Docetaxel
Therapeutic Area: Oncology Product Name: ADI-PEG 20
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
JS001 (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2. It is being developed for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2023
Details:
SBP-101 (ivospemin) is a small molecule AMD1/ODC1 inhibitor. It is being evaluated in phase 3 clinical trials in combination with gemcitabine & nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins. It is approved for the treatment of patients with locally advanced or metastatic biliary tract cancer in China.
Lead Product(s): Durvalumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
Keytruda® (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Lead Product(s): Pembrolizumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
Keytruda (pembrolizumab) in combination with gemcitabine and cisplatin is approved for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).
Lead Product(s): Pembrolizumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2023
Details:
Opdivo (nivolumab) a programmed death-1 (PD-1) immune checkpoint inhibitor, in combination with cisplatin-based chemotherapy is being evaluated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
Lead Product(s): Nivolumab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate malignant glioma more effectively, which is investigated for metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Certepetide,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: LSTA1
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
Opdivo (nivolumab) is a PD-1 inhibitor which is being evaluated along with chemotherapy in phase 3 clinical trials for the treatment of resectable non-small cell lung cancer.
Lead Product(s): Nivolumab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
Keytruda (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Lead Product(s): Pembrolizumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
SOT102 is a potent antibody-drug conjugate that combines the clinically-validated target Claudin 18.2 (CLDN18.2) with a powerful toxin to address gastric, pancreatic and other cancers that have very few targeted treatments available.
Lead Product(s): SOT102,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SOT102
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
Keytruda (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Lead Product(s): Pembrolizumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate malignant glioma more effectively, which is investigated for metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): LSTA1,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: LSTA1
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
VCN-01 is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma that serves as a significant physical and immunosuppressive barrier to cancer treatment.
Lead Product(s): VCN-01,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2023
Details:
9-ING-41 (elraglusib) is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor which is being developed for adults and children with advanced refractory pancreatic cancer cancer.
Lead Product(s): Elraglusib,Gemcitabine
Therapeutic Area: Oncology Product Name: 9-ING-41
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
SBP-101 (ivospemin) is a polyamine analogue designed to induce polyamine metabolic inhibition by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
SBP-101 (ivospemin) is a polyamine analogue designed to induce polyamine metabolic inhibition by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. It is being investigated in combination with chemotherapy for resectable non-small cell lung cancer.
Lead Product(s): Nivolumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
VCN-01, an intravenous oncolytic adenovirus, designed to replicate selectively and aggressively within tumor cells, and degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to Pancreatic Cancer treatment.
Lead Product(s): VCN-01,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
The Company intends to use the net proceeds for the continued clinical development of its product candidates including, SBP-101 (diethyl dihydroxyhomospermine), a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI).
Lead Product(s): Diethyl Dihydroxyhomospermine,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $8.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 21, 2023
Details:
The Company intends to use the net proceeds for the continued clinical development of its product candidates including, SBP-101 (ivospemin), a proprietary polyamine analogue, being developed for the traetment of pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $8.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 16, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
